Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Olivola, Enrica ^a   Pierantozzi, Mariangela ^a   Imbriani, Paola ^a,b   Liguori, Claudio ^a   Bassi, Mario Stampanoni ^a   Conti, Marco ^a   D'Angelo, Vincenza ^a   Mercuri, Nicola Biagio ^a,b   Stefani, Alessandro ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; SEROTONIN;

AGED; APATHY; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PARKINSON DISEASE; PHENOTYPIC VARIATION; SIGNAL TRANSDUCTION; SLEEP DISORDER; UNIFIED PARKINSON DISEASE RATING SCALE; CEREBROSPINAL FLUID; COHORT ANALYSIS; COMPLICATION; METABOLISM; PSYCHOLOGY; PUNCTURE;

AGED; COHORT STUDIES; DEPRESSION; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; PARKINSON DISEASE; SEROTONIN; SPINAL PUNCTURE;

EID: 84904489249     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101763     Document Type: Article

References (28)

1. Goedert M, Spillantini MG, Del Tredici K, Braak H (2013) 100 years of Lewy pathology. Nat Rev Neurol 9: 13-24.
2. Huot P, Fox SH, Brotchie JM (2011) The serotonergic system in Parkinson's disease. Prog Neurobiol 95: 163-212.
3. Mayeux R, Stern Y, Cote L, Williams JB (1984) Altered serotonin metabolism in depressed patients with parkinson's disease. Neurology 34: 642-646. (Pubitemid 14143522)
4. Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, et al. (2010) Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 75: 1920-1927.
5. Loane C, Wu K, Bain P, Brooks DJ, Piccini P, et al. (2013) Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology 80: 1850-1855.
6. Rylander D (2012) The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery. Parkinsonism Relat Disord 18 Suppl 1: S126-128.
7. Kish SJ (2003) Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? Adv Neurol 91: 39-49.
8. Bédard C, Wallman M-J, Pourcher E, Gould PV, Parent A, et al. (2011) Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea. Parkinsonism Relat Disord 17: 593-598.
9. Carlsson T, Carta M, Winkler C, Björklund A, Kirik D (2007) Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci 27: 8011-8022. (Pubitemid 47173327)
10. Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, et al. (2007) Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol 14: 523-528. (Pubitemid 46587839)
11. Roselli F, Pisciotta NM, Pennelli M, Aniello MS, Gigante A, et al. (2010) Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study. Mov Disord 25: 1853-1859.
12. Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, et al. (2003) Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 60: 1223-1229. (Pubitemid 37099627)
13. Politis M, Wu K, Loane C, Kiferle L, Molloy S, et al. (2010) Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis 40: 216-221.
14. Kuhn W, Müller T, Gerlach M, Sofic E, Fuchs G, et al. (1996) Depression in Parkinson's disease: biogenic amines in CSF of "de novo" patients. J Neural Transm 103: 1441-1445.
15. Chia LG, Cheng FC, Kuo JS (1993) Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease. J Neurol Sci 116: 125-134.
16. Kostić VS, Djuricić BM, Covicković-Sternić N, Bumbasirević L, Nikolić M, et al. (1987) Depression and Parkinson's disease: possible role of serotonergic mechanisms. J Neurol 234: 94-96.
17. Abdo WF, De Jong D, Hendriks JCM, Horstink MWIM, Kremer BPH, et al. (2004) Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Mov Disord 19: 571-579.
18. Meco G, Fabrizio E, Di Rezze S, Alessandri A, Pratesi L (2003) Mirtazapine in L-dopa-induced dyskinesias. Clin Neuropharmacol 26: 179-181. (Pubitemid 36951061)
19. LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, et al. (1992) Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group. Neurology 42: 2111-2117.
20. Solla P, Cannas A, Ibba FC, Loi F, Corona M, et al. (2012) Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease. J Neurol Sci. 15; 323:33-39.
21. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, et al. (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9: 573-580.
22. Navailles S, De Deurwaerdère P (2012) Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease. Mol Neurobiol 45: 173-185.
23. Huot P, Johnston TH, Koprich JB, Winkelmolen L, Fox SH, et al. (2012) Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque. Neurobiol Aging 33: 207.e9-19.
24. Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, et al. (2012) Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Mov Disord. 27:84-9.
25. Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ (2011) Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study. Neuroimage 56: 1463-1468.
26. Stefani A, Brusa L, Olivola E, Pierantozzi M, Martorana A (2012) CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD. J Neural Transm 119: 861-875.
27. Lunardi G, Galati S, Tropepi D, Moschella V, Brusa L, et al. (2009) Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 15: 383-389.
28. Engelborghs S, Vloeberghs E, Maertens K, Marescau B, De Deyn PP (2004) Evidence for an association between the CSF HVA:5-HIAA ratio and aggressiveness in frontotemporal dementia but not in Alzheimer's disease. J Neurol Neurosurg Psychiatr 75: 1080. (Pubitemid 38869640)